These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36991547)

  • 1. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.
    Catamero D; Benito PB; Shenoy S; Doyle M; Fowler J; Kobos R; Banerjee A; Kruyswijk S
    Semin Oncol Nurs; 2024 Jun; 40(3):151621. PubMed ID: 38600011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teclistamab in Relapsed or Refractory Multiple Myeloma.
    Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
    N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Graf KC; Davis JA; Cendagorta A; Granger K; Gaffney KJ; Green K; Hess BT; Hashmi H
    EJHaem; 2024 Aug; 5(4):793-797. PubMed ID: 39157607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
    Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S
    Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
    Hamadeh IS; Shekarkhand T; Rueda C; Firestone RS; Wang AX; Korde N; Hultcrantz ML; Lesokhin AM; Mailankody S; Hassoun H; Shah UA; Maclachlan K; Rajeeve S; Patel D; Shah GL; Scordo M; Lahoud OB; Chung DJ; Landau HJ; Giralt S; Usmani SZ; Tan CR
    Blood Adv; 2024 Jun; 8(12):3038-3044. PubMed ID: 38598713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
    Moreau P; van de Donk NWCJ; Delforge M; Einsele H; De Stefano V; Perrot A; Besemer B; Pawlyn C; Karlin L; Manier S; Leleu X; Weisel K; Ghilotti F; Diels J; Elsada A; Morano R; Strulev V; Pei L; Kobos R; Smit J; Slavcev M; Mateos MV
    Adv Ther; 2023 May; 40(5):2412-2425. PubMed ID: 36961654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Teclistamab - A Bispecific CD3 T-cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Kanapuru B; Zhao J; Price LSL; Zheng N; Konicki R; Manning ML; Gehrke BJ; Theoret MR; Gormley NJ
    Clin Cancer Res; 2024 Oct; ():. PubMed ID: 39412823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau O; Calara-Nielsen K; Davis C; Patel J; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg J; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona RI
    Blood; 2024 Aug; 144(6):615-628. PubMed ID: 38657201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study.
    Derman BA; Roach M; Lin D; Wu B; Murphy R; Kim N; Doyle M; Prood N; Fowler J; Marshall A; Jamaleddine A; Paner-Straseviciute A
    Curr Med Res Opin; 2024 May; ():1-6. PubMed ID: 38745451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
    Moreau P; Mateos MV; Gonzalez Garcia ME; Einsele H; De Stefano V; Karlin L; Lindsey-Hill J; Besemer B; Vincent L; Kirkpatrick S; Delforge M; Perrot A; van de Donk NWCJ; Pawlyn C; Manier S; Leleu X; Martinez-Lopez J; Ghilotti F; Diels J; Morano R; Albrecht C; Strulev V; Haddad I; Pei L; Kobos R; Smit J; Slavcev M; Marshall A; Weisel K
    Adv Ther; 2024 Feb; 41(2):696-715. PubMed ID: 38110653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.
    Lipe BC; Renaud T
    J Oncol Pharm Pract; 2023 Jun; 29(4):1006-1010. PubMed ID: 36464766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety outcomes of teclistamab accelerated dose escalation.
    Kawasaki Y; Steele AP; Rosenberg A; Guglielmo J
    J Oncol Pharm Pract; 2024 Aug; ():10781552241268429. PubMed ID: 39090994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis.
    Khouderchah CJ; Ochs M; Pianko M; Mahmoudjafari Z; Snyder J; Ahmed I; Campagnaro E; Nachar VR
    J Oncol Pharm Pract; 2024 Sep; 30(6):1089-1095. PubMed ID: 38576408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teclistamab: Mechanism of action, clinical, and translational science.
    Guo Y; Quijano Cardé NA; Kang L; Verona R; Banerjee A; Kobos R; Chastain K; Uhlar C; Pillarisetti K; Doyle M; Smit J; Haddish-Berhane N; Ouellet D
    Clin Transl Sci; 2024 Jan; 17(1):e13717. PubMed ID: 38266057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
    Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.